BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis.
Bharti V, Watkins R, Kumar A, Shattuck-Brandt RL, Mossing A, Mittra A, Shen C, Tsung A, Davies AE, Hanel W, Reneau JC, Chung C, Sizemore GM, Richmond A, Weiss VL, Vilgelm AE.
Bharti V, et al. Among authors: vilgelm ae.
Cell Rep. 2022 Dec 20;41(12):111826. doi: 10.1016/j.celrep.2022.111826.
Cell Rep. 2022.
PMID: 36543138
Free PMC article.